Weiss Ratings Reaffirms “Sell (D-)” Rating for Entera Bio (NASDAQ:ENTX)

Entera Bio (NASDAQ:ENTX)‘s stock had its “sell (d-)” rating reaffirmed by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright raised shares of Entera Bio to a “strong-buy” rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Entera Bio Price Performance

ENTX stock opened at $2.17 on Wednesday. The company has a market capitalization of $99.08 million, a PE ratio of -8.35 and a beta of 1.68. The firm’s 50-day moving average is $1.91 and its 200 day moving average is $1.93. Entera Bio has a 12 month low of $1.50 and a 12 month high of $2.79.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. Sell-side analysts forecast that Entera Bio will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC grew its stake in Entera Bio by 53.3% during the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after buying an additional 6,310 shares during the last quarter. Parkman Healthcare Partners LLC lifted its stake in Entera Bio by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock worth $747,000 after acquiring an additional 25,900 shares in the last quarter. Finally, Bessemer Group Inc. purchased a new stake in Entera Bio in the 2nd quarter worth about $268,000. 14.11% of the stock is owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.